|Type||Buy / Hold / Sell|
|Year End 30th Jun||Unit||2018||2019||2020||2021||2022||2023E||2024E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
Cryosite Limited is engaged in providing outsourced clinical trials logistic services. The Company manages the entire clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution, and reverse logistics management. Its segments include Clinical Trials, Biological Storage and Logistics, and Cord Blood and Tissue Storage. The Clinical Trials, Biological Storage and Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport solutions and biological storage to the clinical trials, research and pharmaceutical industry. The Cord Blood and Tissue Storage segment provides long term storage for cord blood and tissue samples. Its clients include the medical, pharmaceutical, veterinary and biotechnology industries.
As of Today at 06:05 UTC, shares in Cryosite are trading at AU$0.75. This share price information is delayed by 15 minutes.
Shares in Cryosite last closed at AU$0.75 and the price had moved by +108.33% over the past 365 days. In terms of relative price strength the Cryosite share price has outperformed the ASX All Ordinaries Index by +110.48% over the past year.
There is no consensus recommendation for this security.
The Cryosite dividend yield is 1.33% based on the trailing twelve month period.
Last year, Cryosite paid a total dividend of AU$0.01, and it currently has a trailing dividend yield of 1.33%. We do not have any data on when Cryosite is to next pay dividends.
We do not have data on when Cryosite is to next pay dividends. The historic dividend yield on Cryosite shares is currently 1.33%.
To buy shares in Cryosite you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.75, shares in Cryosite had a market capitalisation of AU$36.61m.
Here are the trading details for Cryosite:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CTE
Based on an overall assessment of its quality, value and momentum Cryosite is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cryosite. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +14.65%.
As of the last closing price of AU$0.75, shares in Cryosite were trading +31.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cryosite PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cryosite's management team is headed by:
- Bryan Dulhunty - CHM
- John Hogg - CEO
- Kim Bradley - SEC
- Andrew Kroger - NED
- Nicola Swift - NED
- Steven Waller - NED